chidamide + regorafenib

**Chidamide + regorafenib** is a combination of two small molecule antineoplastic agents under investigation for cancer therapy. **Chidamide** is a benzamide-based class I histone deacetylase (HDAC) inhibitor, which modulates gene expression and remodels the tumor microenvironment to reduce immunosuppressive cells and enhance T-cell activation[5][4]. **Regorafenib** is a multi-kinase inhibitor that primarily targets vascular endothelial growth factor receptors (VEGFR), among other tyrosine kinases, suppressing tumor growth and angiogenesis[2][5]. The combination is intended to synergistically enhance efficacy: chidamide’s epigenetic modulation may potentiate regorafenib’s anti-angiogenic and anti-tumor activities, while together they can heighten anti-tumor immune responses, as preclinical and early phase clinical data in hepatocellular carcinoma and colorectal cancer suggest improved objective response rate and overall survival[2][5][4].